When two giants diverge: why Eli Lilly raced ahead while Novo Nordisk stumbled

It felt like a tilt-shift moment on the pharma leaderboard: one title-holder sprinting forward and another who’d dominated the same lane suddenly slowing to a stumble. On Wednesday, Eli Lilly’s share price surged after a bullish earnings call and an outsized 2026 revenue outlook, while Novo Nordisk’s stock slid on a gloomy forecast and mounting competitive pressures. The result is a widening gap between the two companies that had been racing in lockstep for the GLP‑1 weight-loss boom. (finance.yahoo.com)

Quick hits: what moved the market

• Eli Lilly raised expectations for 2026 revenue — targeting roughly $80–$83 billion — and beat Q4 estimates, giving investors confidence in continued growth. (finance.yahoo.com)
• Novo Nordisk surprised the market with guidance that implied a 5%–13% sales decline for 2026, signaling pressure from competition, pricing changes and regulatory headwinds. (finance.yahoo.com)
• Broader disruptions — cheaper compounded products, new entrants, and political scrutiny over drug pricing — accelerated the split between the two stocks. (investopedia.com)

How we got here: background and recent events

• The context is the GLP‑1 revolution. Drugs like Lilly’s tirzepatide (Zepbound/Mounjaro family) and Novo’s semaglutide (Wegovy/Ozempic) redefined treatment for obesity and type 2 diabetes and produced rapid revenue growth for both companies in recent years. That boom set up intense competition and sky‑high expectations. (financialcontent.com)

• Eli Lilly’s recent performance combined strong quarterly revenue (Q4 revenue above estimates) with a bold 2026 outlook — and investors interpreted that as evidence Lilly’s manufacturing, distribution and product mix are scaling well. The company’s oral GLP‑1 candidate and expanding market share in obesity care add to the narrative. (finance.yahoo.com)

• Novo Nordisk’s outlook, by contrast, acknowledged a “painful transition” in a market facing price pressure and growing competition. Management signaled slower growth and even a potential sales decline next year — a message that markets punished quickly. Compounding this, cheaper and sometimes legally contested alternatives (and talk of regulatory intervention) have created noise and uncertainty around pricing and volume. (finance.yahoo.com)

Why the stocks diverged — the investor read

• Forecasts matter: investors rewarded Lilly for projecting aggressive top‑line growth and beating quarterly expectations; they punished Novo for guiding to weaker sales. Forecast direction can change how a company is priced more than current-year results. (finance.yahoo.com)

• Product positioning and pipeline: Lilly’s expanding GLP‑1 franchise (including oral programs) and its ability to ramp supply were read as durable advantages. Novo still leads in semaglutide brand recognition, but its comments suggest pricing and uptake will be tougher in 2026. (investing.com)

• Pricing and politics: the U.S. spotlight on drug costs and moves by payers and regulators to curb prices change the math for high‑price specialty drugs. Lower list prices or tougher reimbursement reduce revenue even if patient demand remains large. That dynamic hit Novo’s outlook hard. (financialcontent.com)

• Competitive noise: cheaper compounded formulations and new entrants (or an oral competitor) compress margins and create headline risk; investors reacted to both actual guidance and the possibility of faster price erosion. (investopedia.com)

What this means for investors and the market

• Valuation repricing may be real. Stocks that once moved together now reflect differentiated risk profiles: Lilly seen as growth‑accelerating, Novo viewed as facing short‑term revenue headwinds. That opens trading and allocation decisions for investors who prefer growth vs stability. (marketbeat.com)

• Short‑term volatility will likely persist. Headlines about pricing policies, regulatory rulings on compounded products, trial readouts for oral GLP‑1s, and quarterly guidance will swing sentiment quickly. (investopedia.com)

• Longer-term winners will be decided by execution, not narrative. Lower prices could expand access and volume, which benefits whichever company controls manufacturing, distribution and payer relationships most effectively. Conversely, sharp margin erosion without offsetting volume gains would hurt profits. (financialcontent.com)

Risks and unanswered questions

• Will government and payer pressure force materially lower U.S. prices, and if so, can either company offset that with volume gains? (financialcontent.com)
• Which oral GLP‑1 or alternative delivery platforms will gain market share, and how will side‑effect profiles and adherence affect real‑world outcomes? (investing.com)
• Can either company defend pricing through patented delivery technologies, programmatic partnerships or by driving superior clinical outcomes? (investing.com)

My take

The split between Eli Lilly and Novo Nordisk isn’t a moral victory for one and a knockout for the other — it’s a re‑rating. Markets are reacting to forward guidance, pipeline signals and a changing regulatory environment. Lilly’s optimistic 2026 outlook and operational momentum bought it a premium; Novo’s candid warning about tougher times cost it investor confidence. Over the long run, scale, patient access and pricing mechanics will determine which company translates the GLP‑1 opportunity into sustainable profits. For now, expect headline‑driven moves and a lot of noise as the industry reshuffles.

Sources

• Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge — Yahoo Finance
  https://finance.yahoo.com/news/eli-lilly-stock-surges-after-company-touts-strong-sales-outlook-as-rival-novo-nordisk-continues-plunge-191141074.html

• Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks — Investopedia
  https://www.investopedia.com/hims-and-hers-launches-new-pill-that-sends-shockwaves-across-weight-loss-drugmakers-11900371

• Hims & Hers Is Introducing a Cheaper Wegovy Copycat. Novo Nordisk Stock Falls. — Barron's
  https://www.barrons.com/articles/wegovy-novo-nordisk-stock-hims-hers-copycat-8ad49160

• Novo Nordisk stock climbs out of hole on FDA chief's threat to block Hims and Hers pill — MarketWatch
  https://www.marketwatch.com/story/novo-nordisk-stock-climbs-out-of-hole-on-fda-chiefs-threat-to-block-hims-and-hers-pill-489b68a9

• Novo and Lilly: why the GLP‑1 winners are being re‑rated — MarketBeat analysis
  https://www.marketbeat.com/originals/the-metabolic-split-why-eli-lilly-soars-as-novo-stumbles/

Why your PC feels slow — and the free tool that actually tells you why

You stare at the familiar bars in Windows Task Manager: CPU 18%, Memory 42%, Disk 0%. Everything looks “fine,” but your cursor stutters, apps freeze for a heartbeat, and videos judder. That feeling — when performance problems refuse to show themselves in plain sight — is maddening. I recently read a hands-on piece about one tiny, free tool that turned that guessing game into something tangible: Process Explorer from Microsoft Sysinternals. It doesn’t just show numbers — it exposes the cause.

A smarter lens on system performance

• Task Manager gives you a useful headline: how much CPU, memory, disk, and network are currently in use.
• Process Explorer gives you the byline: which processes or threads are doing the work, which files and handles they have open, what they’re reading from disk, and even whether those processes are known or flagged by security scanners.

Process Explorer is the kind of tool people in IT and power users have relied on for years because it shows the plumbing behind Windows’ behavior. It’s portable (no installation), still maintained by Microsoft, and free. But more than that, it translates confusing symptoms — stutters, periodic freezes, high latency — into observable events you can act on.

How Process Explorer reveals hidden bottlenecks

• Process tree and parent/child relationships: see which process spawned which, and follow the chain to the real culprit (for example, a browser extension process spawned by a tab).
• I/O and thread-level details: add columns like I/O Read Bytes, Private Bytes, and active thread CPU to find background disk or thread storms that keep the system busy even when CPU looks low.
• Lower pane: view open handles and loaded DLLs for any process to find file locks or problematic libraries.
• System Information window: live graphs for CPU, memory, GPU, and I/O let you spot what spiked first during a slowdown.
• VirusTotal integration: submit process hashes to VirusTotal and view aggregated antivirus vendor results directly in the tool (handy for spotting suspicious or mismatched binaries).

Those capabilities change troubleshooting from “I think it’s the browser” to “this browser process is doing continuous disk reads because of one tab’s extension — kill it or close the tab and performance returns.”

Quick setup and sensible first steps

• Download Process Explorer from Microsoft’s Sysinternals site and extract the ZIP — there’s no installer. (Run the EXE as administrator for full details.)
• Optionally replace Task Manager with Process Explorer (Options → Replace Task Manager) so Ctrl+Shift+Esc opens the richer interface.
• Add useful columns: I/O Read Bytes, I/O Write Bytes, Private Bytes, CPU Time. They reveal background activity.
• When you see a slowdown, open View → System Information to check which resource spiked first (CPU, memory, or I/O).
• Right-click suspicious processes and use “Check VirusTotal.com” to get a quick aggregated scan result (remember: VirusTotal aggregates many engines and can show false positives).

Real-world examples that make it worth the switch

• A browser kept reading the disk nonstop — Process Explorer showed a specific tab process with huge I/O reads. Closing that tab solved the lag.
• Defender scheduled a scan of a giant backup folder and caused intermittent spikes. With Process Explorer you can see the pattern and reschedule scans instead of guessing.
• Explorer.exe hung because a shell extension thread was stuck at 100% CPU. Killing that thread fixed the freeze without rebooting.

Those are the small “Aha!” moments after which your laptop suddenly feels snappier because you can target the root cause rather than spin through generic tweaks.

What to watch out for

• VirusTotal column: useful, but not infallible. It aggregates many antivirus engines; occasional false positives or API rate limits are possible. Treat results as signals, not definitive judgments.
• Running as administrator: Process Explorer shows more information with elevated rights. Don’t run elevated constantly unless you need to troubleshoot.
• Portable means responsibility: because it’s a powerful tool, be careful when killing processes — terminating the wrong system process can affect stability.
• Malicious software can attempt to hide from or disable diagnostic tools. If Process Explorer behaves oddly (crashes, can’t show details), that could be a sign of deeper infection or of OS-level protections.

When Process Explorer is the right move

• Intermittent lag without clear resource saturation.
• Apps that “hang” briefly but recover.
• Frequent disk spikes that don’t match visible activity.
• Suspicion of odd or unknown processes, or files running from unexpected locations.

If you regularly fix problems by trial-and-error, Process Explorer will shorten that loop. It makes invisible causes visible.

My take

There’s a difference between seeing metrics and understanding behavior. Task Manager tells you “what,” Process Explorer tells you “why.” For anyone who’s had to play detective on a slow Windows machine, adding Process Explorer to your troubleshooting toolkit is a small step that pays consistent dividends. It won’t replace learning fundamentals (like how memory, I/O, and CPU interplay), but it gives you the facts you need to make sensible fixes — and fewer guesses.

Helpful resources

• Process Explorer (official Microsoft Sysinternals download and documentation) — authoritative download and feature reference.
• VirusTotal (overview and public scanning service) — context on how integrated scanning results are sourced and why they should be interpreted carefully.
• MakeUseOf article that inspired this post — a short, practical write-up showing real examples of using Process Explorer to find causes of slowdowns.

Sources

• Process Explorer – Sysinternals | Microsoft Learn
  https://learn.microsoft.com/en-us/sysinternals/downloads/process-explorer

• VirusTotal | CISA
  https://www.cisa.gov/resources-tools/services/virustotal

• I set up a free system monitor that actually tells me why my PC is slow — MakeUseOf
  https://www.makeuseof.com/set-up-free-system-monitor-that-tells-me-why-pc-slow/